In 1982, the gene TRK was shown to cause a small percentage of colon cancers but by 2013 and 2014, sequencing of tumor samples found fusions of the TRK family of genes in at least 11 tumor types, including lung, breast, melanoma and more.
A recent article in the journal Cancer Discovery describes clinical trials at the University of Colorado Cancer Center and elsewhere that match drugs to this long-overlooked oncogene, offering targeted treatment options for cancers that harbor these gene abnormalities. See ClinicalTrials.gov #NCT02122913.